Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence.

Alcoholism, clinical and experimental research - 1 Feb 2014

Wong Conrad J, Witcher Jennifer, Mallinckrodt Craig, Dean Robert A, Anton Raymond F, Chen Yunfei, Fijal Bonnie A, Ouyang Haojun, Dharia Sweta, Sundseth Scott S, Schuh Kory J, Kinon Bruce J

Abstract excerpt

BACKGROUND: Endogenous opioid-mediated reward pathways may play a role in the development and maintenance of alcohol dependence. This study tested whether LY2196044, an opioid receptor antagonist, in combination with medical management would reduce drinking in alcohol-dependent patients. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcoholism
Share to Benzylamines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diagnostic and Statistical Manual of Mental Disorders

Share to Medication Adherence

Share to Narcotic Antagonists

Share to Niacinamide

Share to Receptors, Dopamine D4

Share to Receptors, Opioid, mu

Source

Identifiers

PMID: 24010675
DOI: 10.1111/acer.12257

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24010675-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence.PMID 24010675Read ↗

Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.Semantic proximity Read ↗

Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction.Semantic proximity Read ↗

Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.Semantic proximity Read ↗

Glucagon-Like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use DisorderSemantic proximity Read ↗

The μ-opioid receptor and treatment response to naltrexone.Semantic proximity Read ↗

Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.Semantic proximity Read ↗

Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics.Semantic proximity Read ↗

Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.Semantic proximity Read ↗

Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1Semantic proximity Read ↗

Pharmacotherapy, Pharmacogenomics, and The Future of Alcohol Dependence Treatment, Part 2Semantic proximity Read ↗

Commentary on Efficacy and Safety of Low dose ondansetron as a prospective precision medicine to treat alcohol use disorder phenotypes.Semantic proximity Read ↗

Opioid pharmacogenetics of alcohol addiction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.